Peginterferon beta-1a - Biocad

Drug Profile

Peginterferon beta-1a - Biocad

Alternative Names: BCD 054; TENEXIA

Latest Information Update: 18 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biocad
  • Class Interferons; Neuroprotectants
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Multiple sclerosis

Most Recent Events

  • 10 Aug 2017 Phase-II/III clinical trials in Multiple sclerosis in Russia (IM) (NCT02744222)
  • 15 Apr 2016 Biocad plans a phase II trial for Multiple sclerosis in Russia (IM) (NCT02744222)
  • 01 Dec 2015 Biocad completes a phase I trial in Healthy volunteers in Russia (IM, SC) (NCT02359877)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top